Administration of the aromatic polycyclic dione compounds hypericin or pseudohypericin to experimental animals provides protection from disease induced by retroviruses that give rise to acute, as well as slowly progressive, diseases. For example, survival from Friend virus-induced leukemia is significantly prolonged by both compounds, with hypericin showing the greater potency. Viremia induced by LP-BM5 murine immunodeficiency virus is markedly suppressed after infrequent dosage of either substance. These compounds affect the retroviral infection and replication cycle at least at two different points: (i) Assembly or processing of intact virions from infected cells was shown to be affected by hypericin. Electron microscopy of hypericin-treated, virusproducing cells revealed the production of particles containing immature or abnormally assembled cores, suggesting the compounds may interfere with processing of gag-encoded precursor polyproteins. The released virions contain no detectable activity of reverse transcriptase. (ii) Hypericin and pseudohypericin also directly inactivate mature and properly assembled retroviruses as determined by assays for reverse transcriptase and infectivity. Accumulating data from our laboratories suggest that these compounds inhibit retroviruses by unconventional mechanisms and that the potential therapeutic value of hypericin and pseudohypericin should be explored in diseases such as AIDS.
gest that these compounds inhibit retroviruses by unconventional mechanisms and that the potential therapeutic value of hypericin and pseudohypericin should be explored in diseases such as AIDS.
We recently reported (1) that two naturally occurring polycyclic aromatic diones, hypericin and pseudohypericin, possess antiretroviral activity. The two compounds, which are derived from the plants of the Hypericum genus (St. Johnswort) (2) (3) (4) (5) , markedly suppress the spread of murine retrovirus infections both in vivo and in vitro (1) . We have now compared the mechanisms of action and the therapeutic potentials of different doses of these agents in two murine retroviral systems. In the Friend virus system (6-8) the compounds can preclude the onset of acute Friend virusinduced erythroleukemia. In the other system a more slowly progressing, fatal form of murine immunodeficiency is induced by the LP-BM5 virus (9, 10) ; hypericin and pseudohypericin prevent development of significant viremia and minimize disease in mice infected with the LP-BM5 virus.
The modes of action of the two agents are unusual.
Hypericin and pseudohypericin interfere with assembly and/ or processing of viral components, significantly decreasing the number of morphologically mature viral particles produced by infected cells without effects on intracellular levels of viral mRNA and viral protein synthesis (1) . In addition, as determined by assays for infectivity and reverse transcriptase, the compounds directly inactivate mouse and human retroviruses, including human immunodeficiency virus (HIV). To our knowledge no other antiretroviral drug possesses the capacity to inactivate directly intact retrovirions as well as interfere with their assembly and/or processing.
MATERIALS AND METHODS Mice. BALB/cJ, BALB/cBy, and C57BL/6J mice used in these studies were bred at our animal facility at New York University Medical Center.
Cell Cultures. AQR and B10.T(6R) murine leukemia cell lines, infected with and secreting radiation leukemia virus (RadLV), were derived and adapted to growth in culture as described (11) . SC1 cells secreting LP-BM5 ecotropic and Mink focus xenotropic virus were a gift from H. C. Morse III (National Institutes of Health). The human CEM T cell line was used to propagate HIV isolated by coculturing blood mononuclear cells from infected individuals with cells from normal donors.
Collection of Blood Samples. Mice were bled from the retroorbital plexus of the eye. Serum was then separated and frozen at -70'C until used.
Viruses, Infectious Procedures, and Reverse Transcriptase Assays. Details and protocols have been published (1, (9) (10) (11) (12) (13) ). An important modification of protocols was introduced that markedly diminishes in vitro toxicities associated with hypericin and pseudohypericin. These agents are always premixed with medium containing 10-20% fetal calf serum before incubation with cells or virions. In addition, the concentrations of cells used for initial exposure to these agents is as high as possible (e.g., 5 x 106 cells per ml). After exposure to the agents, cells are diluted to their normal concentrations for proper in vitro maintenance and growth (2-5 x Although the Friend virus system permits testing the activity of the compounds in an acute infection system, this model has several drawbacks. Transformation of erythroid precursor cells occurs rapidly after virus inoculation. Thus the system permits little delay in the administration of hypericin or pseudohypericin to animals.
To overcome these disadvantages, further studies of the in vivo effects of hypericin and pseudohypericin were conducted on other retroviruses that give rise to slower and gradually progressing disease such as the LP-BM5 murine leukemia virus [which causes the murine acquired immunodeficiency syndrome (MAIDS)]. Mice infected with LP-BM5 virus develop lymphoadenopathy, splenomegaly, hypergammaglobulinemia, T-and B-cell polyclonal proliferation, and profound immunosuppression associated with enhanced susceptibility to infection (9) . Analysis of spleen and lymph node cells from LP-BM5-infected mice has shown many similarities between the early course of this disease and that of HIV-associated AIDS (9) . Fig. 2 shows that injection of LP-BM5 virus into C57BL/6 mice results in onset of viremia after day 21. This viremia is prevented, at least during the 90-day follow-up period, by i. Fig. 3A shows a marked decline in the release ofreverse transcriptase activity into the growth medium. As measured after 24 or 48 hr, 50% inhibition of virus release occurred in the presence of hypericin at -0.1 ,g/ml; complete inhibition for at least 24 hr of virus release was obtained with 1 ,ug/ml. Cell viability was not affected by this treatment.
These findings indicate that release of mature virus detectable by reverse transcriptase assays into the growth medium was inhibited by intracellular or membrane-bound hypericin. Such a result could be explained by inhibition of virus production at any of several steps involved in the virus replication cycle, starting from transcription of proviral DNA. However, we previously showed that hypericin and pseudohypericin do not affect viral mRNA steady-state levels, translation of viral mRNA, or transport of viral proteins to the cell surface (1).
Whether assembly or budding of viral particles is inhibited by hypericin has been examined by EM. In a manner similar to that indicated in Fig. 3A , infected AQR cells that produce RadLV were washed four times with phosphate-buffered saline, incubated for 1 hr with hypericin, fixed, embedded, and sectioned for EM 24 hr later. Electron micrographs show that treatment with hypericin at 10 ,.g/ml does not eliminate particle production (Fig. 3B ) compared with untreated cells (Fig. 3C) cle pelleting during ultracentrifugation (100,000 x g), which occurs before the assay. To investigate this hypothesis, we examined reverse transcriptase activity in both pellets and supernatants from hypericin-treated virus preparations. Reverse transcriptase activity could not be found in either fraction (Fig. 4A and data not shown) , making it unlikely that lysis of virus is the mechanism for elimination of viral reverse transcriptase activity by hypericin or pseudohypericin. Reverse transcriptase (RT) analyses after direct exposure of virus to hypericin (e) and pseudohypericin (o). Virus was collected from AQR cells producing RadLV and exposed to hypericin for 1 hr at 40C (A) and CEM cells producing HIV exposed to hypericin and pseudohypericin for 1 hr at 370C (B). Virus was then pelleted at 50,000 x g, lysed with 0.5% Triton X-100, and analyzed for reverse transcriptase.
bly and budding. Elsewhere (F.V., D.M., V. Itri, and (14, 15) . Studies in both the avian and murine retrovirus systems have shown that viral particles can be formed in the absence of envelope glycoproteins (15) (16) (17) (18) (19) (20) , reverse transcriptase (15, (21) (22) (23) , or genomic RNA (15, 24, 25) . By contrast, physical particles are not generated when avian virus gag-related polyproteins are either not cleaved or synthesized (15, (26) (27) (28) (29) .
It has been shown with murine retroviruses that the maturation of the core structure after virus budding, as seen in EM, may relate to cleavage of the precursor polyproteins (15, 30, 31) . Deletion mutations in the protease regions of the virus genome have been shown to lead to the production of immature forms of virus core (15, 32 nificantly different biological activities, enables a preliminary insight into structure-function relationships. With a main common structural feature of a flat core of eight fused aromatic rings encircled by six phenolic hydroxyls (see Fig.  5 ), the substitution for the seventh hydroxyl group that occurs in pseudohypericin clearly diminishes antiretroviral activity. Further study of this structure-function relationship may help guide development of even more powerful antiretroviral agents.
An important aspect of the biological activity of hypericin and pseudohypericin, only briefly demonstrated in this manuscript, is their anti-HIV activity. The anti-HIV activity of these compounds will be further documented elsewhere. Data presented here, in ref. 1 , and in the work to be published indicate the need to perform the requisite studies of preclinical toxicology and clinical trials to determine the potential therapeutic value of hypericin and pseudohypericin in diseases such as AIDS.
